Literature DB >> 23846782

Trends in incidence and management of lobular carcinoma in situ: a population-based analysis.

Pamela R Portschy1, Schelomo Marmor, Rumbidzayi Nzara, Beth A Virnig, Todd M Tuttle.   

Abstract

PURPOSE: Lobular carcinoma in situ (LCIS) is a marker of increased risk of breast cancer. Current guidelines do not recommend mastectomy as a strategy for risk reduction for most patients with LCIS. We conducted a population-based study to evaluate national trends in incidence and management of LCIS.
METHODS: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort analysis of women diagnosed with microscopically confirmed LCIS from 2000 through 2009. We excluded patients with invasive breast cancer or ductal carcinoma in situ. We evaluated variation in treatment, including biopsy alone, excision, excision with radiation therapy, and mastectomy. We utilized logistic regression to identify time trends, demographics, and patient factors associated with mastectomy.
RESULTS: We identified 14,048 patients diagnosed with LCIS from 2000 to 2009. The rate of LCIS incidence increased from 2.0 per 100,000 in 2000 to 2.75 per 100,000 in 2009 (38 % increase). Of these patients, 10 % underwent biopsy only, 73 % underwent excision alone, 1 % underwent excision with radiation, and 16 % underwent mastectomy. Mastectomy rates were significantly higher among white and younger women. The proportion of women with LCIS to receive mastectomy increased by 50 % from 2000 to 2009 (p < 0.01). Mastectomy rates varied significantly based on geographic region ranging from 12 to 24 %.
CONCLUSIONS: This is the first population-based analysis evaluating patterns and trends in surgical management of LCIS. Despite current recommendations, risk-reduction surgery is increasingly performed in the United States for women with LCIS.

Entities:  

Mesh:

Year:  2013        PMID: 23846782     DOI: 10.1245/s10434-013-3121-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Maeve Mullooly; Zeina G Khodr; Cher M Dallal; Sarah J Nyante; Mark E Sherman; Roni Falk; Linda M Liao; Jeffrey Love; Louise A Brinton; Gretchen L Gierach
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races.

Authors:  Li-Yuan Yang; Li-Peng Yang; Biao Zhu
Journal:  Oncotarget       Date:  2017-07-19

3.  Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.

Authors:  Lauren J Taylor; Jennifer Steiman; Jessica R Schumacher; Lee G Wilke; Caprice C Greenberg; Heather B Neuman
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

4.  The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.

Authors:  Monica G Valero; Emily C Zabor; Anna Park; Elizabeth Gilbert; Ashely Newman; Tari A King; Melissa L Pilewskie
Journal:  Ann Surg Oncol       Date:  2019-09-26       Impact factor: 5.344

5.  Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

Authors:  Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

6.  Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.

Authors:  Bruno Cutuli; Brigitte De Lafontan; Youlia Kirova; Hugues Auvray; Agnes Tallet; Sandrine Avigdor; Claire Brunaud; Catherine Delva
Journal:  Radiat Oncol       Date:  2015-05-06       Impact factor: 3.481

7.  Pharmacodynamics and Medicinal Chemistry of an External Chinese Herbal Formula for Mammary Precancerous Lesions.

Authors:  Ruixue Chen; Guijuan Zhang; Yi Ma; Fengjie Bie; Hongxia Fan; Min Ma
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-24       Impact factor: 2.629

8.  Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study.

Authors:  Pu Cheng; Qi Huang; Jiafeng Shou; Guoming Hu; Mengjiao Han; Jian Huang
Journal:  Oncotarget       Date:  2017-10-03

9.  Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status.

Authors:  Kai Mao; Yaping Yang; Wei Wu; Shi Liang; Heran Deng; Jieqiong Liu
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

10.  A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.

Authors:  Henry Beetham; Augustine Chen; Bryony J Telford; Andrew Single; Kate E Jarman; Kurt Lackovic; Andreas Luxenburger; Parry Guilford
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.